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In lung cancer cyclooxygenase-2 (COX-2) expression has been reported to stabilise survivin, an inhibitor of apoptosis (IAP) which
prevents cell death by blocking activated caspases. COX-2 expression limits the ubiquitination of survivin, protecting it from
degradation. To determine if COX-2 expression in breast cancer showed an association with survivin expression, we assessed the
levels of each protein in ductal carcinoma in situ (DCIS) and invasive breast cancer (IBC); relating expression patterns to recurrence of
DCIS after surgery. Patterns of COX-2 and survivin expression were determined by intensity-graded immunohistochemistry of the
primary tumours. Patients with DCIS (n¼161) which had either recurred (n¼47) or shown no evidence of recurrence (n¼114) 5
years following primary surgery were studied. These were compared to 58 cases of IBC. Survivin was expressed in the cytoplasm of
59% of DCIS and 17% of IBC. High levels of both cytoplasmic survivin and COX-2 expression significantly correlated to DCIS
recurrence. COX-2 expression was present in 72% of DCIS, and levels of expression positively correlated with cytoplasmic survivin
expression in DCIS and invasive disease. The majority of DCIS that recurred expressed both proteins (69%) vs 39% nonrecurrent.
Recurrence was not seen in DCIS lacking both proteins at 5 years (P¼0.001). Expression of the IAP survivin is increased in DCIS and
correlates closely with COX-2 expression. Increased expression of IAP, (leading to reduced apoptosis) may explain the effect of
COX-2 in increasing recurrence of DCIS after surgical treatment.
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The incidence of the preinvasive breast cancer ductal carcinoma in
situ (DCIS) has increased by over five-fold since the introduction
of national screening programs (Ernster et al, 2000). The
recurrence rate in the NSABP B-17 trial at 10 years following
breast conserving surgery and radiotherapy remains at almost 12%
(Fisher et al, 1986). There is, therefore, a need to identify novel
predictors of recurrence risk and potential targets for therapy.
Cyclooxygenase-2 (COX-2) is an inducible rate-limiting enzyme in
the conversion of arachidonic acid to prostaglandins. It is induced
by a number of promoters including c-erbB2/(HER2) and NFkb
(Smith et al, 2000). We have previously shown that COX-2
expression is related to a poor prognostic phenotype of DCIS
(Boland et al, 2004), but there are no published data on whether
COX-2 expression affects recurrence of DCIS. Survivin is a
member of the inhibitors of apoptosis protein (IAP) family, which
includes proteins such as X-IAP, H-IAP and survivin (Ambrosini
et al, 1997; Schimmer, 2004), that have effects on both cell cycle
regulation and apoptosis. The antiapoptotic properties of the IAP’s
lie in their ability to block the activation of caspases (mainly 3, 7
and 9) in the cell cytoplasm, which are key regulators of classical
apoptosis (Schimmer, 2004). In addition to their antiapoptotic
effects, IAP’s have been shown to regulate cell cycle progression
and cell signalling (Schimmer, 2004). Survivin is expressed in fetal
tissues but is absent from normal terminally differentiated cells
(Ambrosini et al, 1997) (except the basal colon epithelial cells
where it may act to limit the stem cell population (Zhang et al,
2001)). It is, however, overexpressed in a wide range of human
invasive cancers including breast (Tanaka et al, 2000), colon
(Kawasaki et al, 1998), gastric (Lu et al, 1998), endometrial (Saitoh
et al, 1999) and lung (Monzo et al, 1999). COX-2 overexpression
has been shown to stabilise survivin in nonsmall cell lung cancer
by preventing its ubiquitination (Krysan et al, 2004) leading to the
decreased rates of apoptosis seen in COX-2 overexpressing lung
tumours.
The aim of the study was to determine the correlation between
COX-2 and survivin expression in DCIS and their relationship to
expression levels in invasive disease and recurrence after surgery.
MATERIAL AND METHODS
Immunohistochemistry
Archival blocks of formalin-fixed paraffin-embedded tissue were
selected, following confirmation that the blocks contained either
pure DCIS or invasive breast cancer (IBC) by an experienced
breast pathologist (WFK). Staining for estrogen receptor (ER),
HER2 and Ki67 and COX-2 have been previously described
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s(Boland et al, 2004). For survivin, the slides were dewaxed in
xylene and rehydrated through graded alcohols. Following
immersion in 0.2% H2O2 in methanol for 10min, the slides were
placed in citrate buffer for antigen retrieval under pressure.
Nonspecific binding was blocked with 10% normal goat serum in
phosphate-buffered saline (PBS), with avidin. The primary anti-
survivin antibody (Ab469 AbCam, Cambridge UK) was diluted
1:400 in normal goat serum/PBS with biotin and incubated on the
slides at 41C overnight. Following further washes in PBS, the
biotinylated goat anti-rabbit antibody secondary (BA-1000, Vector,
UK) was applied for 1h. After washing in PBS, the sections were
incubated in ABC Vectastain elite reagent (Vector, UK) for 35min.
Staining was visualised with DAB, slides counterstained with 20%
haematoxylin, dehydrated, cleared and mounted.
Evaluation of immunostaining
Staining was assessed by light microscopy without the knowledge
of clinico-pathological features or patient outcome. For ER and
Ki67 the percentages of positively staining nuclei were determined.
At least 1000 cells were counted for each case, at  400
magnification. ER status was taken to be positive if X5% of cells
were labelled. The membranous and cytoplasmic staining of HER2
was assessed semiquantitatively using the proportion of positively
staining cells and degree of staining intensity compared to adjacent
normal tissue; samples scored 0 to 3þ as previously described
(Boland et al, 2004). The cytoplasmic staining of COX-2 was scored
0 (absent) to 3þ (strong) based on the extent and intensity of
staining as previously described (Boland et al, 2004), COX-2
positivity was defined as a score of X2. Survivin staining was
scored for both cytoplasmic and nuclear staining independently.
The AbCam ab469 antibody used has been shown to detect all
three splice variants of survivin (Fortugno et al, 2002) which
together are present in both the cytoplasm and the nucleus.
Cytoplasmic staining was scored 0 (absent) to 3þ (strong); scores
of X2 taken as positive. When cells displayed nuclear survivin the
proportion of positive cells out of at least 1000 was determined
(Figure 1).
Patient selection
Women diagnosed with pure DCIS (n¼161) between 1979 and
1999 were selected, of which, 47 had recurred within 5 years
(median time to recurrence 21 months; range 10–60) and 114 were
recurrence free after 5 years of follow-up. In all, 13 of the
recurrences were invasive disease and 34 were further DCIS. Breast
conserving surgery had been performed in 60 of the nonrecurrent
and 43 of the recurrent DCIS, and mastectomy in 39 nonrecurrent
and eight of the recurrent cases. In our department women with a
DCIS exceeding 4cm would be considered for mastectomy rather
than breast conserving surgery. Current policy is to ensure that all
wide local excision samples have at least 1mm clear surgical
excision margins. However, this data set used archival specimens,
a subset of which did not have clear margins (as they were treated
before the benefit of clear margins was proven) therefore, margin
status was included in the multivariate analysis of the results.
There were not sufficient recurrences following mastectomy to
identify significant differences in the nature of recurrence between
the mastectomy and breast conserving surgery groups. A random
selection of patients with IBC who had undergone surgery between
1980 and 1999 were selected from a tumour bank in our
department to compare COX-2 and survivin expression in invasive
disease. It was ensured that the invasive samples represented all
tumour grades in similar proportions to the DCIS sample. Tumour
nuclear grade was determined following review of the original
pathology report. Ethical approval was given by the South
Manchester University Hospital Ethics Board.
Statistical analysis
The relationship between receptor coexpression tumour size,
nuclear grade, ER status and recurrence were assessed by the w
2
test. The relationship between Ki67 and receptor expression was
assessed using the Kruskal–Wallis test. Correlation coefficients
were generated using Spearman’s nonparametric correlation.
Kaplan–Meier survival plots were generated with log-rank
significance. The multivariate analysis was performed using the
COX proportional hazards analysis. Significance tests were two-
tailed and 5% significance level was used throughout. Analysis was
carried out using SPSS 10.0 for windows.
RESULTS
Survivin expression in DCIS
In total 102 cases of DCIS were stained for survivin; 69 with no
evidence of recurrence at 5 years and 33 with recurrence by 5 years
of follow-up. The remaining blocks had insufficient tissue left as
COX-2, ER, Ki67 and HER2 staining had already been performed.
Survivin was present in both the cytoplasmic and nuclear
subcellular compartments. In all, 32 cases (31%) showed no
survivin staining (nuclear or cytoplasmic), 10 of 102 (10%) showed
nuclear staining alone, 30 of 102 (29%) showed both cytoplasmic
and nuclear staining and 30 of 102 (29%) showed cytoplasmic
staining alone. The DCIS that recurred was significantly more
likely to express moderate to strong (2 to 3þ) levels of
cytoplasmic survivin (76%) compared to 37% of nonrecurrent
disease (P¼0.0001) (Table 1). Cytoplasmic survivin expression
score correlated with COX-2 expression score (Spearman’s
correlation coefficient 0.322, P¼0.001). None of the 10 cases that
showed nuclear survivin alone recurred within 5 years (Table 1).
There were no significant associations between cytoplasmic
survivin expression and the clinico-pathological factors of age,
nuclear grade, pathological tumour size, ER, HER2, HER4 status or
proliferation (Ki67) (data not shown).
COX-2 expression in DCIS
As we have previously demonstrated (Boland et al, 2004), COX-2
was highly expressed in the cytoplasm of DCIS cells. Overall, 116 of
the 161 cases studied (72%) were COX-2 positive (scores of
Figure 1 Immunohistochemical staining for surviving. (A) Cytoplasmic
survivin positive DCIS 3þ;( B) Cytoplasmic survivin positive DCIS 2þ;
(C) Nuclear survivin alone in DCIS. (D) IBC showing cytoplasmic survivin
1þ.
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smoderate or strong staining). Greater COX-2 expression was seen
in DCIS that recurred than the nonrecurrent cases (P¼0.010;
Table 1). The majority of DCIS that recurred expressed moderate
or strong COX-2 (Table 1). Only one of the 47 cases that recurred
expressed no COX-2 (2%) and only five (11%) expressed weak
COX-2 (Table 1), compared to 16% (18/114) and 18% (21/114)
cases of nonrecurrent DCIS expressing none or weak staining,
respectively. We have previously demonstrated that COX-2
expression correlated with the Type 1 Tyrosine kinase receptor
c-erbB2/HER2 expression (Boland et al, 2004) and this association
was upheld in this new series of women (Spearman’s correlation
coefficient 0.271, P¼0.001).
Differential survivin staining in DCIS vs IBC
To assess the differences between survivin expression between
DCIS and IBC a panel of 58 IBC’s were stained for survivin
and COX-2. The grade variation of the invasive cancer was chosen
to be similar to that of the DCIS, with six (10.7%) of the invasive
cases being grade 1, 13 (23.2%) grade 2 and 37 (66.1%) grade 3.
Overall, survivin was expressed at moderate to strong levels in
10/58 (17%) of IBC, compared to 60 of 102 (60%) of patients
with DCIS (P¼0.0001; Table 1). IBC showed weak staining in a
further 23 of 58 (40%) of cases. The distribution of nuclear
and cytoplasmic survivin also differed significantly between IBC
and DCIS, with a higher proportion of invasive cases showing
nuclear staining alone 24 of 58 (41%), compared to 10 of 102
(10%) cases of DCIS. Fewer cases of IBC showed evidence of
cytoplasmic survivin expression, both alone (12 vs 30%), or with
coexisting nuclear survivin (5 vs 29%) (Table 1). There was no
difference in COX-2 expression, in this dataset, between DCIS
and IBC.
The presence of cytoplasmic survivin correlated with COX-2
expression in IBC (correlation coefficient 0.28, P¼0.004) as it did
in DCIS. No IBC expressed survivin without COX-2.
Cytoplasmic survivin and COX-2 coexpression relates to
DCIS recurrence
Overall, 13 (17%) cases of DCIS expressed neither protein, 29
(28%) expressed COX-2 alone, nine (8%) expressed cytoplasmic
survivin alone and 51 (50%) expressed both proteins.
Of the cases that recurred 70% (n¼23) expressed both COX-2
and cytoplasmic survivin. In contrast, none of the cases that did
not express either protein (n¼13) recurred within 5 years
(P¼0.013) (Table 2). Coexpression patterns did not relate to cell
proliferation, tumour nuclear-grade, ER or HER2 status (Table 2).
The relationship between COX-2, survivin and DCIS recurrence
was upheld when looking only at the cases that had undergone
breast conserving surgery (P¼0.021) (Table 2).
When the 5-year cumulative disease free survival was plotted
against cytoplasmic survivin status as Kaplan–Meier graphs, DCIS
that was cytoplasmic survivin positive (scores of 2 and 3þ) had a
significantly poorer 5-year outcome than cytoplasmic survivin
negative cases (scores of 0 and 1þ) (Figure 2A and B). The
number of DCIS cases recurring by 5 years also increased with
increasing COX-2 score (Figure 2C). We have shown that COX-2
expression is related to the Type 1 Tyrosine kinase receptor HER2
expression (Boland et al, 2004). From the Kaplan Meier plot for
COX-2 and HER2 expression, it is the tumours that express both
factors that have a significantly poorer recurrence-free survival
advantage over any other group (Figure 2D).
On combining COX-2 and cytoplasmic survivin coexpression
(Figure 2E), the cases that express both survivin and COX-2 have
the highest 5-year recurrence. Tumours that are both COX-2 and
cytoplasmic survivin negative having the greatest disease-free
survival advantage; with none of the cases in this series with both
receptors negative recurring by 5 years.
In a multivariate analysis, higher cell-proliferation (P¼0.006;
Exp(B)1.034; 95% Confidence interval (CI) 1.01–1.06), higher
nuclear-grade (P¼0.003; Exp(B) 3.899; 95% CI 1.58–9.61) and
Table 1 COX-2 and survivin expression by tumor type
Invasive cancer Total DCIS Nonrecurrent DCIS DCIS with 5 year recurrence
Survivin subcellular staining pattern
No staining 24 (41%) 32 (31%) 24 (35%) 8 (24%)
Nuclear only 24 (41%) 10 (10%) 10 (14%) 0 (0%)
Cytoplasmic only 3 (5%) 30 (29%) 17 (25%) 13 (39%)
Nuclear and cytoplasmic 7 (12%) 20 (29%) 19 (28%) 12 (37%)
P-value 0.0001 0.045
Cytoplasmic survivin score
0 25 (43%) 18 (18%) 14 (20%) 4 (12%)
1+ 23 (40%) 24 (24%) 20 (29%) 4 (12%)
2+ 7 (12%) 32 (31%) 21 (30%) 11 (33%)
3+ 3 (5%) 28 (27%) 14 (20%) 14 (42%)
P-value 0.0001 0.05
Cytoplasmic survivin score X2 10 (17%) 60 (59%) 35 (51%) 25 (76%)
P-value 0.0001 0.016
COX-2 score
0 3 (5%) 19 (12%) 18 (15%) 1 (2%)
1+ 11 (19%) 26 (16%) 21 (18%) 5 (11%)
2+ 20 (34%) 45 (28%) 36 (31%) 12 (26%)
3+ 25 (42%) 71 (44%) 32 (36%) 29 (62%)
P-value n/s 0.09
COX-2 score X2 45 (78%) 116 (72%) 78 (67%) 41 (87%)
P-value n/s 0.08
NOTE: n/s¼ not statistically significant.
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shigher COX-2 score (P¼0.019; Exp(B) 1.632; 95% CI 1.09–2.46)
were all independent predictors of increased recurrence of DCIS
(also included in the analysis were surgical margin status
(P¼0.700), HER2 status (P¼0.131) and age at diagnosis
(P¼0.419)). The addition of survivin did not aid the model as
the two factors correlate in expression frequency.
DISCUSSION
COX-2 as a predictor of recurrence and therapeutic target
COX-2 expression in DCIS is a potential predictor of recurrence as
well as a therapeutic target. Our own data from breast cancer cell
lines, indicates that COX-2 expression inhibits apoptosis, and
Celecoxib (a COX-2 inhibitor) reduces xenograft growth by
increasing cell death (with no effects on cell proliferation) in a
nude mouse model (Barnes et al, 2004).
Here, we have shown that COX-2 expression is associated with
early recurrence of DCIS (within 5 years of surgery) and is usually
associated with survivin expression. We have shown that the
cytoplasmic expression of survivin correlates with COX-2 expres-
sion and DCIS recurrence. In this study, staining was prioritised
for the evaluation of COX-2 and survivin, insufficient tissue
remained on enough blocks after this staining for the additional
evaluation of markers of apoptosis. However, COX-2 expression
has previously been demonstrated to correlate with low-apoptotic
rates (Liu et al, 2001). This supports the hypothesis that the
expression of these two factors is linked via the stabilisation of
survivin by COX-2 (as found by Krysan et al, 2004) in non-small
cell lung cancer), leading to the inhibition of apoptosis. The net
effect of which would be to increase the longevity of survivin, thus
inhibiting the caspase pathway and increasing cell survival.
Cytoplasmic survivin expression increases recurrence risk
In IBC, previous studies of survivin protein expression range from
60 (Chu et al, 2004) to 94% (Ryan et al, 2005). Overall, we were
able to demonstrate the presence of survivin in 74% of IBC and
73% of DCIS, with DCIS showing stronger expression levels than
invasive cancer; indicating that survivin expression may be an
early event in the malignant process.
Survivin, when present in the cell cytoplasm, was associated
with increased recurrence of DCIS. We found no correlation
between nuclear survivin and recurrence risk. This is a logical
finding, as when survivin is in the nucleus it is sub-cellularly
distinct from the caspases, which it blocks – which are present and
function in the cell cytoplasm. Survivin is, however, a nuclear
shuttling protein that exists in three splice variants; wild-type
survivin, survivin-2B and survivin delta Ex3. The survivin and
survivin 2B splice variants are more often found in the cytoplasm,
whereas the delta Ex3 is more frequently found in the nucleus
(Rodriguez et al, 2002). The antibody we used in this study, detects
all three splice variants and further work to characterise the impact
of each of these splice variants on recurrence risk needs to be
undertaken. Full understanding of whether the differing recur-
rence/cell signalling effects seen with nuclear vs cytoplasmic
survivin are due to the subcellular location, or the differential
functions of the splice variants remains to be seen. Antibodies to
the separate splice variants are not yet commercially available for
use in immunohistochemistry.
Predicting recurrence risk
The optimum treatment of DCIS is still controversial. In the USA,
many cases of DCIS do not receive radiotherapy after breast
conserving surgery (Baxter et al, 2004). Prediction of recurrence
risk in both DCIS (and invasive cancer), by way of receptor
expression profiling may aid decisions about the need for
radiotherapy. Panels of robust indicators of recurrence risk (both
clinico-pathological and molecular-biological) could potentially be
utilised as routine, to direct individual patient treatment.
Identifying patients both at high risk of recurrence, who would
require close postoperative radiotherapy and also patients with
good prognostic factors that may well be able to avoid unnecessary
adjuvant radiotherapy or Tamoxifen.
In this study, we have shown for the first time that lack of COX-2
expression is a predictor of a decreased risk of DCIS recurrence,
Table 2 COX-2 and cytoplasmic survivin co-expression in DCIS
Protein coexpression
COX-2 22++
Cytoplasmic Survivin 2 + 2 + P-value
Overall number (%) 13 (17) 9 (8) 29 (28) 51 (50)
Median Ki67 (%) (n¼102) 8.7 9.1 11.0 14.4 n/s
Range 1.6–33.5 3.4–40.7 1.6–47.2 2.0–61.1
Low grade (n¼8) (%) 0 (0) 2 (25) 4 (50) 2 (25) n/s
Intermediate grade (n¼33) (%) 8 (24) 2 (6) 8 (24) 15 (45)
High grade (n¼60) (%) 4 (7) 5 (8) 17 (28) 34 (57)
ER negative (n¼36) (%) 3 (8) 3 (8) 12 (28) 18 (50) n/s
ER positive (n¼63) (%) 9 (14) 6 (10) 16 (25) 32 (51)
HER2 negative (n¼36) (%) 7 (19) 4 (11) 11 (31) 14 (38) n/s
HER2 positive (n¼66) (%) 6 (9) 5 (14) 18 (27) 37 (56)
Number no recurrence (%) (n¼69) 13 (19) 7 (10) 21 (30) 28 (41) 0.013
Number recurred (%) (n¼33) 0 (0) 2 (6) 8 (24) 23 (70)
Recurrence type
DCIS 0 1 7 16
Invasive 0 1 1 7
Breast conserving surgery only
Number No recurrence (%) (n¼39) 6 (15) 4 (10) 15 (38) 14 (36) 0.021
Number recurred (%) (n¼29) 0 (0) 1 (3) 8 (21) 20 (51)
NOTE: n/s¼ not significant; (n¼xx) is the total number of patients assessed for each parameter.
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sthat is, DCIS that recurs is rarely COX-2 negative. The potential
prediction of early recurrence is enhanced upon determining the
coexpression of COX-2 and cytoplasmic survivin, as no cases that
expressed neither protein in this series recurred within 5 years.
This study was a retrospective look at a large number of DCIS
cases. It would be beneficial to look in a prospective series of
patients – such as at randomised trial follow up to validate our
findings.
In IBC, no cases expressed survivin without COX-2, but in DCIS,
survivin was present in nine of 102 cases (9%), which lacked
COX-2. There must, therefore, be alternate pathways through
which survivin is stabilised which are independent of COX-2.
Alternatively, the ultimate inducer of COX-2 and survivin may be
controlled by up stream, potential candidates being the NFkBo r
HER2/Ras pathways. In DCIS, COX-2 expression correlated with
HER2, thus understanding the downstream signalling via Ras to
COX-2 and survivin splice variants warrants further study.
Inhibiting survivin as a therapeutic target
Survivin and other IAP’s have been reported to be upregulated in
several malignancies, including breast cancer (Kawasaki et al,
A
Time (months)
60 50 40 30 20 10 0
R
e
c
u
r
r
e
n
c
e
 
f
r
e
e
 
s
u
r
v
i
v
a
l
1.0
0.9
0.8
0.7
0.6
0.5
0.4
B
Time (months)
60 50 40 30 20 10 0
R
e
c
u
r
r
e
n
c
e
 
f
r
e
e
 
s
u
r
v
i
v
a
l
1.0
0.9
0.8
0.7
0.6
0.5
Survivin neg
Survivin pos
1+
0
2+
3+
P=0.0350 log rank
C
Time (months)
60 50 40 30 20 10 0
R
e
c
u
r
r
e
n
c
e
 
f
r
e
e
 
s
u
r
v
i
v
a
l
1.0
0.9
0.8
0.7
0.6
0.5
D
Time (months)
60 50 40 30 20 10 0
R
e
c
u
r
r
e
n
c
e
 
f
r
e
e
 
s
u
r
v
i
v
a
l
1.0
0.9
0.8
0.7
0.6
0.5
3+
2+
1+
0
HER2 pos/COX-2 pos
HER2 neg/COX-2 pos
HER2 neg/COX-2 neg
HER2 pos/COX-2 neg 
P=0.0335 log rank
 
P=0.0018 log rank
E
Time (months)
60 50 40 30 20 10 0 –10
R
e
c
u
r
r
e
n
c
e
 
f
r
e
e
 
s
u
r
v
i
v
a
l
1.0
0.9
0.8
0.7
0.6
0.5
COX2 pos/survivin pos
COX2 pos/survivin neg
COX2 neg/survivin pos
COX2 neg/survivin neg
P=0.0146 log rank   
 
Figure 2 Higher expression of both survivin (A and B) and COX-2 (C) were associated with increased cumulative 5-year recurrence. DCIS that
expressed both COX-2 and HER2 (D) or COX-2 and survivin (E) had the poorest 5-year recurrence-free survival.
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s1998; Lu et al, 1998; Monzo et al, 1999; Saitoh et al, 1999; Tanaka
et al, 2000), compared to normal tissue. Phase I clinical trials using
the Isis/Eli-Lilly novel survivin RNA antisense inhibitor
(LY21818308) are underway to exploit this expression.
In summary, the presence of cytoplasmic survivin correlates
with COX-2 expression and recurrence. High expression of
both proteins relates to an increased risk of recurrence of
DCIS. Assessing the levels of these proteins may identify
patients, who could avoid radiotherapy after breast conserving
surgery for DCIS. Future use of inhibitors to both these proteins
either alone or in combination offer potential new anticancer
interventions.
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